مقایسهٔ روشها
روشهای انتخابی خود را کنار هم مرور کنید؛ ردیفهای متفاوت برجسته شدهاند.
| ارزیابی عملیاتی ابزار غربالگری× | ارزیابی آزمون غربالگری× | |
|---|---|---|
| حوزه | اپیدمیولوژی | اپیدمیولوژی |
| خانواده | Process / pipeline | Process / pipeline |
| سال پیدایش≠ | 2000s-2010s (formalized with PRECIS framework) | 1968 (Wilson-Jungner principles); statistical framework developed 1970s–2000s |
| پدیدآور≠ | Pragmatic trial framework: Schwartz & Lellouch (1967); PRECIS tool: Thorpe et al. (2009) | Wilson & Jungner (WHO criteria, 1968); foundational work by Pepe, Altman, and others in statistical test evaluation |
| نوع≠ | Observational / quasi-experimental evaluation design | Observational diagnostic / epidemiological evaluation design |
| منبع بنیادین≠ | Thorpe, K. E., Zwarenstein, M., Oxman, A. D., Treweek, S., Furberg, C. D., Altman, D. G., & Chalkidou, K. (2009). A pragmatic-explanatory continuum indicator summary (PRECIS): a tool to help trial designers. Journal of Clinical Epidemiology, 62(5), 464-475. DOI ↗ | Wilson, J. M. G., & Jungner, G. (1968). Principles and Practice of Screening for Disease. World Health Organization. Public Health Papers No. 34. link ↗ |
| نامهای دیگر | pragmatic diagnostic screen evaluation, real-world screening evaluation, effectiveness-oriented screening study, PRECIS-guided screening evaluation | screening study, screening performance evaluation, screening accuracy assessment, STE |
| مرتبط≠ | 5 | 6 |
| خلاصه≠ | A pragmatic screening test evaluation assesses the real-world effectiveness of a screening instrument under routine clinical or public-health conditions — rather than the tightly controlled, ideal-participant settings of explanatory studies. It asks whether the screening tool performs adequately in the actual populations and workflows where it will be deployed, prioritising external validity and implementation relevance over maximally controlled internal conditions. | Screening test evaluation is a systematic epidemiological approach for assessing whether a test or program can accurately and cost-effectively identify individuals with a condition before symptoms appear. It quantifies diagnostic performance metrics — sensitivity, specificity, predictive values, and the ROC curve — and evaluates whether a screening program meets established public health criteria for adoption and harm-benefit balance. |
| ScholarGateمجموعهداده ↗ |
|
|